CO5150193A1 - DIHIDROXIACIDO ABIERTO Y SALES DE INHIBIDORES DE LA HMG-CoA REDUCTASA - Google Patents

DIHIDROXIACIDO ABIERTO Y SALES DE INHIBIDORES DE LA HMG-CoA REDUCTASA

Info

Publication number
CO5150193A1
CO5150193A1 CO00016008A CO00016008A CO5150193A1 CO 5150193 A1 CO5150193 A1 CO 5150193A1 CO 00016008 A CO00016008 A CO 00016008A CO 00016008 A CO00016008 A CO 00016008A CO 5150193 A1 CO5150193 A1 CO 5150193A1
Authority
CO
Colombia
Prior art keywords
open
dihydroxiacide
hmg
inhibitors
salts
Prior art date
Application number
CO00016008A
Other languages
English (en)
Inventor
Richard D Tillyer
Paul J Reider
Edward J J Grabowski
Lili Feng
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CO5150193A1 publication Critical patent/CO5150193A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica oral que comprende una cantidad terapéuticamente eficaz de un compuesto seleccionado entre una estatina en su forma de dihidroxiácido abierto y una sal ó éster farmacéuticamente aceptables de ésta junto con un vehículo portador farmacéuticamente aceptable, composición farmacéutica formulada en una forma de dosificación de liberación retardada en donde la liberación sustancial del compuesto a partir de la forma de dosificación a un paciente se retarda hasta después del paso de la forma de dosificación a través del estómago.<EMI FILE="00016008_1" ID="1" IMF=JPEG >
CO00016008A 1999-03-08 2000-03-06 DIHIDROXIACIDO ABIERTO Y SALES DE INHIBIDORES DE LA HMG-CoA REDUCTASA CO5150193A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12322799P 1999-03-08 1999-03-08
US26474499A 1999-03-09 1999-03-09
PCT/US2000/002626 WO2000053173A1 (en) 1999-03-08 2000-02-02 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors

Publications (1)

Publication Number Publication Date
CO5150193A1 true CO5150193A1 (es) 2002-04-29

Family

ID=26821357

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00016008A CO5150193A1 (es) 1999-03-08 2000-03-06 DIHIDROXIACIDO ABIERTO Y SALES DE INHIBIDORES DE LA HMG-CoA REDUCTASA

Country Status (9)

Country Link
EP (1) EP1161236A1 (es)
JP (2) JP2002538202A (es)
AR (1) AR022856A1 (es)
AU (1) AU2866400A (es)
CA (1) CA2364253A1 (es)
CO (1) CO5150193A1 (es)
PE (1) PE20001559A1 (es)
SV (1) SV2002000036A (es)
WO (1) WO2000053173A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523948A (ja) * 1999-11-04 2003-08-12 アンドルクス コーポレーション アミロイドβ前駆体障害の治療法
EP1324972A4 (en) * 2000-09-06 2004-06-30 Merck & Co Inc OPEN-CHAIN DIHYDROXY ACID SALT BY SIMVASTATIN
SK4112003A3 (en) * 2000-10-12 2004-01-08 Nissan Chemical Ind Ltd Preventives and remedies for complications of diabetes
KR20040026705A (ko) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
EP1425287A4 (en) * 2001-08-16 2005-09-07 Teva Pharma PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINES
AU2003206251B2 (en) * 2002-01-09 2008-03-13 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US8987322B2 (en) 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE602004020649D1 (de) * 2003-11-07 2009-05-28 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
WO2015055857A1 (en) * 2013-10-18 2015-04-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Rny-derived small rnas as biomarkers for atherosclerosis-related disorders
EP3624789B1 (en) 2017-05-15 2024-09-25 University of Cincinnati Compositions comprising metabolites of simvastatin for use in repairing or retarding damage to avascular cartilaginous tissue by direct administration to the avascular tissue
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
DE122011000014I1 (de) * 1995-12-22 2011-11-03 Kowa Co Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium.
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor

Also Published As

Publication number Publication date
JP2000256191A (ja) 2000-09-19
PE20001559A1 (es) 2001-01-16
JP2002538202A (ja) 2002-11-12
EP1161236A1 (en) 2001-12-12
CA2364253A1 (en) 2000-09-14
WO2000053173A1 (en) 2000-09-14
AR022856A1 (es) 2002-09-04
AU2866400A (en) 2000-09-28
SV2002000036A (es) 2002-02-05

Similar Documents

Publication Publication Date Title
CO5150193A1 (es) DIHIDROXIACIDO ABIERTO Y SALES DE INHIBIDORES DE LA HMG-CoA REDUCTASA
AR064895A2 (es) Composicion farmaceutica anhidra para el tratamiento de desordenes inducidos por histamina
CO5690131A1 (es) Derivados de eter biarilico que presentan actividad como inhibidores de la recaptacion de monoaminas para el tratamiento de transtornos del snc
CO5271657A1 (es) Derivados de azaindol
CO5570109A1 (es) Compuestos de dihidropirimidina heterociclicos
ATE296641T1 (de) Orale formulierung zur verabreichung in den ileum enthaltend einen hemmstoff des ileum- gallensäuretransports
RU2008111710A (ru) Композиция для чрескожной доставки лекарственного средства
BG104619A (en) Oral pharmaceutical pulsed release dosage form
CO5270017A1 (es) Prevencion de ruptura de placa por inhibidores acat
GEP20002013B (en) Therapeutical Means
DE60020825D1 (de) Pharmazeutische zusammensetzungen die dipeptidylpeptidase iv inhibitoren enthalten zur förderung des wachstums
BR9407749A (pt) Derivados de ácido processo para a preparaçao dos mesmos e composiçoes farmacêuticas
EP2036558A3 (en) Orally administrable opioid formulations having extended duration of effect
AU2681300A (en) Solid oral dosage form containing an enhancer
EP0866656A4 (en) INHIBITING THE ALPHA TUMORNESCROSE FACTOR
CO5271736A1 (es) Forma triturada
RU93055870A (ru) Производные бифенила, способ их получения и фармацевтическая композиция для лечения гипертонии и сердечных заболеваний
CO5420196A1 (es) Compuestos inhibidores de metaloproteasa bidentes, composi- ciones farmaceuticas que los contienne y metodos para su utilizacion
EA200300110A1 (ru) Композиция элетриптана в виде частиц
CO5150233A1 (es) Formulacion de liberacion controlada para administrar un inhibidor de pde4
CA2299423A1 (en) Taste-masked pharmaceutical composition
RU2011108587A (ru) Новые метилендиоксифенольные соединения и их применение для лечения заболеваний
AR032614A1 (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
CO5160291A1 (es) Composicion farmaceutica topica que contiene 4-(2,4-dihidroxifenil) ciclohexanol
CO5170463A1 (es) Formas polimorfas de un citrato de azobiciclo [2,2,2]octan- 3-amina y sus composiciones farmaceuticas